Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 13/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 9/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.47 |
| ▸ | WDR5 | P61964 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495550 | 0.90 | P2RX3 (0.47) | AKR1C3AKR1C4AKR1C2AKR1C1HDAC1 | |
| SCHEMBL1495394 | 0.90 | AKR1C3 (0.50) | AKR1C3AKR1C4AKR1C2AKR1C1WDR5 | |
| SCHEMBL1495587 | 0.88 | AKR1C3 (0.48) | AKR1C3AKR1C4AKR1C2AKR1C1WDR5 | |
| SCHEMBL1495375 | 0.87 | AKR1C3 (0.48) | AKR1C3AKR1C4AKR1C2AKR1C1WDR5 | |
| SCHEMBL1495489 | 0.87 | AKR1C3 (0.51) | AKR1C3AKR1C4AKR1C2AKR1C1WDR5 | |
| SCHEMBL2382517 | 0.84 | WDR5 (0.57) | AKR1C3AKR1C4AKR1C2AKR1C1WDR5 | |
| SCHEMBL12757613 | 0.83 | P2RX3 (0.47) | P2RX3P2RX2 | |
| SCHEMBL1495407 | 0.81 | L3MBTL1 (0.52) | ALDH1A1 | |
| SCHEMBL27981586 | 0.81 | AKR1C3 (0.50) | AKR1C3AKR1C4AKR1C2AKR1C1WDR5 | |
| SCHEMBL12831351 | 0.80 | WDR5 (0.48) | AKR1C3AKR1C4AKR1C2AKR1C1WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | claimed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | IL1B, ADORA2B, AVPR1B | AKR1C3 973/4885AKR1C4 1109/4885AKR1C2 1626/4885 |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | IL1B, ADORA2B, AVPR1B | AKR1C3 973/4885AKR1C4 1109/4885AKR1C2 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.